A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92037, United States
Miami, Florida 33136, United States
Topeka, Kansas 66606-1707, United States
Baltimore, Maryland 21202-2102, United States
Charlotte, North Carolina 28204, United States
Pittsburgh, Pennsylvania 15213, United States
Salt Lake City, Utah 84132, United States
Seattle, Washington 98104, United States
Seoul, Seoul 03080, South Korea